Omeros Newsroom

Rodman & Renshaw Maintains Omeros(OMER.US) With Buy Rating, Cuts Target Price to $9

Moomoo NewsNov 14 07:32 ET

Rodman & Renshaw Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $9

BenzingaNov 14 06:54 ET

Needham Maintains Omeros(OMER.US) With Hold Rating

Moomoo NewsNov 14 05:33 ET

Omeros Analyst Ratings

BenzingaNov 14 05:25 ET

Omeros Analyst Ratings

BenzingaJun 4 05:47 ET

Omeros Analyst Ratings

BenzingaMay 16 06:42 ET

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Cullinan Management (CGEM) and Omeros (OMER)

TipRanksMay 16 06:36 ET

Omeros (OMER) Gets a Hold From Needham

TipRanksMay 16 06:30 ET

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)

TipRanksApr 9 07:45 ET

Omeros Analyst Ratings

BenzingaNov 10, 2023 15:44 ET

Omeros' Clinical Trials Setbacks and Financial Standing Lead to Underperform Rating: An Analysis

TipRanksOct 16, 2023 18:55 ET

UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating

MT NewswiresMar 15, 2023 11:15 ET

Bank of America Securities Keeps Their Sell Rating on Omeros (OMER)

TipRanksMar 14, 2023 06:47 ET

Analysts Offer Insights on Healthcare Companies: Omeros (OMER) and SAGE Therapeutics (SAGE)

TipRanksFeb 7, 2023 07:07 ET

Needham Reaffirms Their Hold Rating on Omeros (OMER)

TipRanksFeb 6, 2023 11:56 ET

Omeros Analyst Ratings

Benzinga Analyst RatingsDec 8, 2022 08:32 ET

UBS Downgrades Omeros to Neutral, Lowers Price Target to $2

Benzinga Real-time NewsDec 8, 2022 08:32 ET

Needham Reaffirms Their Hold Rating on Omeros (OMER)

TipRanksNov 10, 2022 06:35 ET

BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target Is $3

MT NewswiresNov 9, 2022 08:51 ET

Omeros Analyst Ratings

Benzinga Analyst RatingsNov 8, 2022 13:47 ET